B细胞成熟抗原(BCMA)NEX-T®嵌合抗原受体(CAR)T细胞疗法CC-98633/BMS-986354在三重暴露多发性骨髓瘤受试者中的1期临床试验
这项1期临床试验评估了采用优化NEX-T®工艺制备的自体BCMA CAR T细胞BMS-986354在三重暴露复发难治多发性骨髓瘤患者中的表现。65例受试者中位既往治疗线数为5,91%为三重难治;A部分剂量递增设20、40、80×10^6 CAR+T细胞组,B部分在推荐2期剂量40×10^6扩增23例。总缓解率95%,完全缓解率46%,中位无进展生存期12.3个月(95%CI 11.3-16)。
要点
- 65例三重暴露复发难治多发性骨髓瘤患者接受BMS-986354,中位既往治疗5线,91%三重难治。
- 细胞因子释放综合征发生率82%(≥3级2%),神经毒性8%(≥3级2%),感染32%(≥3级5%)。
- 总缓解率95%,完全缓解率46%,中位无进展生存期12.3个月(95%CI 11.3-16)。
核心结论
- BMS-986354在三重暴露复发难治多发性骨髓瘤中显示出高缓解率和可控毒性,NEX-T®工艺支持未来CAR T开发。
研究设计与样本
- 1期临床试验,A部分剂量递增设20(N=7)、40(N=24)、80(N=11)×10^6 CAR+T细胞组,B部分在推荐2期剂量40×10^6扩增23例,共65例三重暴露复发难治多发性骨髓瘤受试者。
主要发现
- 65例受试者中位既往治疗5线(范围3-13),39%细胞遗传学高危,91%三重难治,43%髓外病变。
- 细胞因子释放综合征发生率82%(≥3级2%),神经毒性8%(≥3级2%),感染32%(≥3级5%)。
- 总缓解率95%,完全缓解率46%,中位无进展生存期12.3个月(95%CI 11.3-16)。
- 与orvacabtagene autoleucel(相同CAR结构、传统工艺)相比,BMS-986354的T中央记忆细胞比例更高、分化更少,效力和增殖能力增强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BCMA-targeted CAR T-cells transformed the treatment of relapsed and refractory multiple myeloma (RRMM), yet improvements are needed in manufacturing, toxicity and efficacy. We conducted a phase 1 clinical trial of BMS-986354, an autologous BCMA CAR T manufactured using an optimized NEX-T® process, in participants with triple-class exposed, RRMM. The 65 participants had a median of 5 (range 3-13) prior regimens, 39% had cytogenetic high-risk, 91% triple-class refractory, and 43% extra-medullar disease. Part A (dose-escalation) of the study enrolled participants in cohorts receiving 20 (N = 7), 40 (N = 24), or 80 (N = 11)x 106 CAR + T-cells. In part B (expansion), an additional 23 participants were treated at the recommended phase 2 dose, 40 ×106 CAR + T cells. Across dose levels, cytokine release syndrome (CRS) occurred in 82% (2% grade ≥3), neurotoxicity in 8% (2% grade ≥3), and infections in 32% of participants (5% grade ≥ 3). The response rate was 95%, with 46% achieving complete responses. Median progression-free survival was 12.3 months (95% CI 11.3-16). Compared to orvacabtagene autoleucel (same CAR construct, conventional manufacturing), BMS-986354 had higher proportion of T central memory cells, were less differentiated and had enhanced potency and proliferative capacity, supporting the use of NEX-T® in future CAR T development.
引用
- Ravi G, Richard S, Kumar S, et al. Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025. PMID: 39910285. doi:10.1038/s41375-025-02518-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。